We can’t show the full text here under this license. Use the link below to read it at the source.
Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use
Thyroid cancer risk linked to using glucagon-like peptide 1 receptor drugs
AI simplified
Abstract
Data from 101,732 participants showed low numbers of thyroid cancer events associated with glucagon-like peptide 1 receptor agonist (GLP-1RA) use.
- Hazard ratios for overall thyroid cancer risk were 1.70 and 1.83 for pooled GLP-1RA compared to placebo and active comparators, respectively.
- Cardiovascular outcome trials indicated a hazard ratio of 1.41 for pooled GLP-1RA versus placebo.
- Post-marketing surveillance indicated a thyroid cancer reporting rate of 0.001 cases per 100 patient-years.
- No association was supported between liraglutide or semaglutide exposure and thyroid cancer events in the post-marketing data.
- Analysis of real-world data showed a hazard ratio of 0.87 for thyroid cancer occurrence in GLP-1RA users compared to sodium-glucose cotransporter-2 inhibitors.
AI simplified
Key numbers
1.70
Thyroid Cancer Hazard Ratio
Hazard ratio for pooled GLP-1RA vs. pooled placebo.
0.001 cases/100 PYE
Thyroid Cancer Reporting Rate
Post-marketing surveillance data for liraglutide and semaglutide.
0.87
MarketScan Hazard Ratio
Hazard ratio for GLP-1RA users vs. SGLT2i users.